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BACKGROUND AND AIM
This review was undertaken with an
eye of providing an evidence-based guide
for internists in the utilization of the vari-
ous techniques in the diagnosis of pul-
monary emboli. Pulmonary angiography
represents a group of tests that are used
alone or in combination to evaluate for the
presence of pulmonary emboli (PE)† and
encompasses computed tomography (CT)
pulmonary angiography (which is noninva-
sive), catheter digital subtraction angiogra-
phy (DSA) (which requires a right heart
catheterization), as well as magnetic reso-
nance imaging (MRI) angiography. All
forms of angiography require the use of
intravenous contrast. CT pulmonary
angiography and, to a lesser extent, con-
ventional DSA (as it has to be performed
by an interventional radiologist) are avail-
able emergently in almost all centers.
Magnetic resonance imaging (MRI)
angiography currently is limited to the clin-
ical research setting and is limited by the
cost and time it takes to perform a study.
INDICATIONS FOR PULMONARY
ANGIOGRAPHY
• CT and invasive DSA are used in the
investigation of suspected pulmonary
embolism.
• CT angiography is now performed as a
first line test to evaluate clinically sus-
pected pulmonary embolism [1].
Negative CT angiography studies
allowanticoagulationtobesafelywith-
held [2, 3], and CT angiography pro-
vides a definitive diagnosis in the
majority of cases [4-6].
• DSA (catheter angiography) remains the
gold-standard test providing an
unchallenged diagnosis in 96 percent
of cases [7], which when negative,
can be used to withhold anticoagula-
tion [8].
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ther investigate inconclusive pul-
monary embolism testing performed
by other modalities; e.g., intermediate
or low probability V:Q scan in the
correct clinical setting or an unex-
plained positive D-Dimer test.
SELECTING PATIENTS AT HIGHER
RISK AND POORER PROGNOSIS
A subset of patients with pulmonary
embolism present with circulatory col-
lapse (shock) and refractory hypoxemia
require an emergent definitive diagnosis in
order to initiate potentially life-saving
therapies.
The Management Strategies and
Determinants of Outcome in Acute
Pulmonary Embolism Trial (MAPPET)
reviewed 1,001 patients at 204 centers and
found an in-hospital mortality rate of 31 per-
cent in patients with hemodynamic instabili-
ty [9]. A prospective, 296 patient, single-
institution study [10], showed that those
patients who did not have cancer, heart fail-
ure, previous deep vein thrombosis (DVT),
systolic blood pressure < 100 mmHg, arteri-
alPaO2<8kPa,orthepresenceofdeep-vein
thrombosis on ultrasound were less likely to
have recurrent thromboembolic event, major
bleeding, or die at three months.
The International Cooperative
Pulmonary Embolism Registry (ICOPER)
trial reviewed 2,454 consecutive patients in
52 hospitals for acute pulmonary embolism
and identified PE in 2,110 patients (86 per-
cent) [11]. The primary outcome of the
study revealed an overall 3-month crude
mortality of 17.4 percent. Markers of poor
prognosis include age over 70 years (haz-
ard ratio 1.6 [95 percent CI 1.1 to 2.3]),
cancer (2.3 [1.5 to 3.5]), congestive heart
failure (2.4 [1.5 to 3.7]), chronic obstruc-
tive pulmonary disease (1.8 [1.2 to 2.7]),
systolic arterial hypotension (2.9 [1.7 to
5.0]), tachypnea (2.0 [1.2 to 3.2]), and
right-ventricular hypokinesis on echocar-
diography (2.0 [1.3 to 2.9]) [12, 13].
Based on the above studies the fol-
lowing conclusion can be drawn:
• Hemodynamically stable patients with
PE have a much lower mortality (1.8-
4.1 percent) compared to hemody-
namically unstable patients with PE
(mortality = 31 percent).
• Over 50 percent of the mortality of all
cases of pulmonary embolism occurs
within the first hour, and, therefore,
hemodynamically unstable PE is a
diagnostic emergency [14].
• Patients with clinical shock should be
considered candidates for potentially
life-saving therapies, including
thrombolysis, pulmonary angiograph-
ic catheter based embolectomy or sur-
gical pulmonary artery embolectomy.
• Markers of poor prognosis include age
over 70 years, cancer, congestive heart
failure, chronic obstructive pulmonary
disease, systolic arterial hypotension,
tachypnea, and right-ventricular
hypokinesis on echocardiography.
INCREASING THE PRETEST
PROBABILITY OF A POSITIVE
TEST
• EKG signs: tachycardia, recent surgery,
previous thromboembolic event, older
age, band atelectasis, or elevation of a
hemi diaphragm on chest x-ray
(CXR) film, right bundle branch
block (RBBB), S1Q3T3, or non-spe-
cific T wave changes [15, 16].
• Increased alveolar-arterial gradient on
room air blood gas. In one study, a
room air blood gas that is not elevated
(alveolar arterial blood gas gradient <
15 mm Hg ) in patients without a his-
tory of deep vein thrombosis or prior
PE is sensitive in excluding PE (1
false-negative in 57 patients) sensitiv-
ity 1.8 percent (95 percent CI 0.9 per-
cent to 10.7 percent) [17].
• Positive high-sensitivity D-Dimer with a
CXR showing no other cause for unex-
plained hypoxemia.Ameta-analysis of
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high sensitivity of 94 percent (95 per-
cent CI 0.88 to 0.97) but poor speci-
ficity of 45 percent [95 percent CI 0.35
to 0.55] for diagnosing venous throm-
bo-embolic disease. [18].
• Bedside echocardiography showing pul-
monary hypertension and RV dilation
and no inspiratory collapse of inferior
vena cava. Echocardiographic studies
reveal a poor sensitivity of approxi-
mately 40 to 56 percent but a high
specificity of approximately 90 per-
cent for diagnosing PE when com-
pared to angiography [19-22].
• Indeterminate V:Q scan.
CONTRA-INDICATIONS TO
PULMONARY ANGIOGRAPHY
(CATHETER OR CT)
All contra-indications to invasive and
non-invasive angiography are relative [23,
24], and there are specific therapies that
can be applied to reduce the risk of
adverse events in high-risk patients [25].
High-risk patients should be well hydrated
and administered non-ionic, iso-osmolar
contrast material at a minimal dose [23,
26, 27]. In a prospective survey of 109,546
patients stratified into high-risk and low-
risk groups receiving ionic and non-ionic
contrast media, respectively, it was con-
cluded that fewer adverse drug reactions
were noted in high-risk patients receiving
non-ionic contrast than in those low-risk
patients receiving ionic contrast [28].
Patients at high-risk groups for
adverse reactions to radiographic contrast
administration include those with:
• Prior contrast reactions. The most impor-
tant risk factor for an allergic contrast
reaction is a prior contrast reaction [29].
•Abnormal renal function (elevated creati-
nine). All patients with impaired renal
function should be considered high
risk. Risk increases with decreasing
renal function and volume of contrast
injected [30-34]. Contrast side-effects
(nephropathy and hypersensitivity) are
reduced with the use of non-ionic con-
trast [28]. Nephrotoxic drugs such as
aminoglycosides and non-steroidal
anti-inflammatory increase the risk of
post contrast renal dysfunction [23].
Patients with multiple myeloma [35]
or diabetes without renal dysfunction
are not at higher risk for nephrotoxici-
ty [36].Acetylcysteine may be of ben-
efit in minimizing contrast induced
renal impairment in patients with pre-
existing renal dysfunction [37].
• Abnormal cardiac function.
• Significant allergies. Shell fish and
seafood allergies are no more signifi-
cant in predicting adverse contrast
reaction than any other allergy [30,
38]. Pretreatment with steroids for sig-
nificant allergies is warranted [24, 39].
•Asthma. Even well-controlled asthma is a
risk factor for contrast reaction [30].
Patients with significant reactive air-
way disease can be pretreated with
steroids [24, 39].
• Patients receiving contrast with pre-
existing conditions including cardiac
disease may aggravate pre-existing
arrhythmias, precipitate angina or
congestive heart failure; pheochromo-
cytomas may lapse into hypertensive
crises; myasthenia gravis may experi-
ence acute worsening of respiratory
symptoms of myasthenia; uncon-
trolled hyperthyroidism may enter a
thyroid storm; sickle cell patients can
experience sickle cell crisis; and those
with paroxysmal nocturnal hemoglo-
binuria may experience worsening of
symptoms [23, 34]. Patients with
pheochromocytoma should be pre-
treated with a beta blocker prior to
contrast administration [23].
• Patients treated with nephrotoxic drugs,
interleukin-2, or metformin. Cancer
patients on interleukin-2 experience
predominantly systemic reactions and
are treated symptomatically [40-42].
As Metformin may induce lactic aci-
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diabetes on metformin should have
their metformin stopped 48 hours in
advance of the scan and should not
resume metformin before 48 hours
after contrast administration and until
renal function has been checked [46]
• Pregnancy is a relative contra-indication to
CT angiography and is safer than V:Q
scanning. The relative radiation dose to
afetusislesswithCTangiographythan
with V:Q scanning if scanning is not
extended caudal to 5 mm inferior to the
xiphoid process [48].The safety of con-
trastagentshasnotbeenproveninpreg-
nancy or lactation.
• For catheter angiography, left bundle
branch block (LBBB) and increased
right ventricular end diastolic pressure
also increase the risk of complications.
TREATMENT OF COMPLICATIONS
• Treatment of intra- or post-procedure
adverse contrast reactions is sympto-
matic [23]. Adverse drug reactions
occur in 3.8 to 12.66 percent (0.09 to
0.22 percent severe) with ionic con-
trast and 1.2 to 3.13 percent (0.02 to
0.04 percent severe) with non-ionic
contrast [28, 38]. Extravasation of
contrast media into soft tissues sur-
rounding a vein during an injection
can lead to tissue damage from direct
toxicity of the contrast agent or from
pressure effects, such as a compart-
ment syndrome. No specific treatment
has been shown unequivocally to be
effective, so most extravasation
injuries are treated conservatively
with supportive measures [46].
• Specifically in those at high risk, pre-
treatment with steroids may help
reduce the risk of hypersensitivity [32,
47, 49]. Pre-treatment of pheochromo-
cytoma patients with beta blocker is
essential [23]. The incidence of renal
toxicity and further deterioration in
those with preexisting renal failure
may be reduced by the use of pre-pro-
cedure isotonic hydration or the use of
non-ionic iso-osmolar contrast agents
[27, 36, 50, 51]. No other drugs (e.g.,
diuretics, calcium channel blockers)
have been shown to reduce the inci-
dence of renal toxicity either prior to
or post administration of contrast [53].
• For patients with allergies or prior con-
trast reaction, methylprednisone at 32
mg at 12 and 2 hours prior to the con-
trast study with or without 50 mg
diphenhydramine one hour before the
study has been recommended [39, 46].
• In a large study of 1,350 catheter
angiograms with ionic contrast mater-
ial, right ventricular end diastolic pres-
sure over 20 mm Hg was associated
with a slightly higher mortality [52].
In addition, this study also showed 17
myocardial conduction complications
with six deaths and 20 direct cardiac
traumas due to catheter manipulation.
A study performed 15 years later of
547 patients with non-ionic contrast
and modern (curved/pigtail) catheters
showed no effect of pulmonary artery
pressure on mortality or complica-
tions, no cardiac perforations, and two
myocardial conduction complications
with no deaths [54]. Minor bruising
and pain may occur at the site of punc-
ture. The EKG strip should be moni-
tored by a dedicated person during the
procedure as LBBB can progress to
RBBB with catheter manipulation in
the right ventricle. To minimize the
risk of complications, patients should
have selective catheterization of the
pulmonary arteries with low-contrast
volume and non-ionic contrast.
CONSIDERATIONS IN CHOOSING
CATHETER ANGIOGRAPHY
• Catheter angiography is accurate (96 per-
cent give unchallenged diagnosis) and
carries a low-risk profile (0.9 to 1.5
percent major and 4.8 to 5 percent
158 Safriel and Hull: Diagnosing pulmonary emboliminor complication rate), which is
lower than empiric anticoagulation [2,
7, 54-58].
• If an angiogram is negative, anticoagula-
tion may be safely withheld [8].
• Patients with right ventricular end dias-
tolic pressure over 20 mm Hg and
pulmonary artery pressure of over 70
mm HG are associated with greater
mortality [52]. Consider unilateral
pulmonary angiography in patients
with severe pulmonary hypertension
if catheter angiography is deemed
imperative.
• Patients with a LBBB should have a
transvenous pacing lead placed in the
event of complete heart block.
• Catheter angiography is weaker in the
detection of small peripheral emboli
as compared with large central emboli
(yet it is still better than CT angiogra-
phy) [55, 59].
CONSIDERATIONS IN CHOOSING
CT ANGIOGRAPHY
CT angiography is readily available,
does not require an interventional radiolo-
gist, and offers the best chance of a diag-
nosis of the non-invasive tests. CT angiog-
raphy is definitive, providing high sensi-
tivity and specificity (Table 1). Two meta-
analyses of CT angiography of 1,250
patients [60] and 1,171 patients [61]
showed a sensitivity of 74 percent, and 88
percent specificity of 90 percent and 92
percent, respectively, for the detection of
PE. Up to 53 percent of patients can have
a definitive diagnosis other than PE con-
firmed with CT, and 88 percent of patients
without PE can have other findings of clin-
ical significance [2, 4-6].
• CT angiography can be performed on all
standard spiral CT scanners and is
therefore available virtually at all
hours at all hospitals. CT angiography
may be effectively interpreted by
trainees in excluding life-threatening
emboli [62]. CT angiography has
replaced V:Q scanning as the first-line
study in practice guidelines outside
the United States [63].
• The radiation dose from CT angiography
is lower than invasive angiography
and, with thin collimation and high
pitch, is equivalent to the background
radiation a person receives from the
environment in one year [64, 65]. CT
angiography is safer to a fetus than
V:Q scanning. V:Q scanning carries a
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Table 1. Operating characteristics for CT pulmonary angiography in diagnosing
acute pulmonary emboli.higher radiation dose to the fetus than
CT angiography [48].
• CT angiography has a higher likelihood
of a definitive diagnosis than V:Q
scanning. A recent meta-analysis of
more than 7,000 patients noted that a
combination of V:Q scanning with
clinical correlation and D-dimer
results could be very effective to
exclude PE. However, the study noted
that CT scanning alone may be as
effective [66]. Prior studies on CT
angiography were misleading in that
they included data from before the
advent of spiral CT scanning and,
therefore, gave a false sense of superi-
ority of V:Q scanning [67].
• CT can also show findings that may
mimic symptoms of PE such as
atelectasis, pleural effusions, pneu-
monia, nodules, and masses.
• Well-tested clinical models exist to
improve the usefulness of the poor
sensitivity specificity of V:Q scan-
ning. CT angiography may be used
effectively to evaluate an intermediate
probability V:Q scan [68].
• CT angiography has a three-month nega-
tive predictive value of 95 to 100 per-
cent [3, 6, 68, 70] and is similar to the
negative predictive value of a normal
or very low probability V:Q scan [3,
69], while a positive CT angiogram
has similar positive predicative value
to V:Q scanning [61].
• If a CT is negative for PE, there is no
need for further imaging or anticoag-
ulation [2, 3, 6, 58, 69].
• Physicians who are trained as chest radi-
ologists have a better ROC curve than
general radiologists who are in turn
better than non-radiologists [71, 72].
Ergo, experienced radiologists are
better at detecting pulmonary emboli
than those with relatively less experi-
ence [72]. However, residents are
capable of providing preliminary
interpretations that will detect life-
threatening pulmonary emboli [62].
• CTpulmonaryangiographyisweakerthan
catheter angiography at detecting
peripheral, smaller emboli [7, 59, 69,
73, 74].
ALTERNATIVES TO PULMONARY
ANGIOGRAPHY
There are no absolute contraindica-
tions to CT or invasive angiography.
Nevertheless, if any relative con-
traindications exist, another technique may
be attempted as a first-line investigation as
long as the patient is not hemodynamically
unstable. [23, 60, 75-77, 91]. In hemody-
namically stable patients, other techniques
in combination (V:Q scanning with D-
Dimer results and clinical suspicion) can
yield acceptable results (under 3 percent
failure rate) in the diagnosis of PE [66].
ELISA D-dimer or high sensitivity
second generation latex agglutination D-
dimer: A meta-analysis of 11 prior D-
dimer trials shows that a negative ELISA
D-Dimer has 94 percent sensitivity for
excluding pulmonary embolism. A posi-
tive result has a poor specificity of only 45
percent [18]. Sensitivity of first generation
non ELISA D-Dimer testing (latex agglu-
tination) is only 70 percent [7].
V:Q scanning can be used as an alter-
native test if CTpulmonary angiography is
deferred. According to the Prospective
Investigation of Pulmonary Embolism
Diagnosis study (PIOPED), patients with a
high clinical suspicion may have an embo-
lus despite a low probability test.
Furthermore, V:Q scanning may not pro-
vide a definitive diagnosis in up to 75 per-
cent of patients [55]. When V:Q scanning
is positive in the appropriate clinical set-
ting, it has high sensitivity and when neg-
ative in the appropriate clinical setting has
high specificity [55], and its efficacy may
be increased if clinical models are used
where V:Q scanning is used in combina-
tion with D-dimers and clinical suspicion
[66]. Additional testing, however, is fre-
quently required to achieve a diagnosis
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scintigraphy) and therefore V:Q scans
have been mostly replaced by CT angiog-
raphy as a first-line investigation [63, 75,
79]. V:Q scanning is not as readily avail-
able after hours as CT angiography and
takes considerably longer, and there is a
higher fetal radiation dose in pregnant
patients [48].
Evaluation of the lower extremity
venous system is used as an adjunct in the
diagnosis of deep-vein thrombosis that
may co-exist with PE. Sensitivity is over
90 percent for venous thrombosis in lower
extremity [80-82], but this may not be use-
ful in non-occlusive thrombosis [83], and a
single negative lower extremity ultrasound
does not exclude pulmonary emboli [84]. It
is of note that only 30 to 50 percent of
patients with PE have a positive leg ultra-
sound [85, 86] and that 25 percent of
patients with intermediate probability lung
scans and serial negative Doppler scans
have PE. Lower extremity ultrasound does
not add any additional details when CT
pulmonary angiography is performed [6,
61]. Between 8 to 18 percent of patients
without PE may have deep venous throm-
bosis demonstrated by CT venography [87,
88]. CT venography has a sensitivity of
94.3 percent and specificity of 92.1 percent
for the detection of deep venous thrombo-
sis [88]. CT venography has not yet
entered routine use as it carries a relatively
high dose especially to the gonads [64, 88]
and there is no method of stratifying before
scanning which patients will require the
additional CT venography evaluation.
Furthermore, the absence of thrombosis in
the lower extremity does not exclude PE
[84]. Therefore, ultrasound continues to
play a primary role in the evaluation of the
lower extremity venous system.
TECHNICAL DETAILS:
CT ANGIOGRAPHY
• CT pulmonary angiograms must be per-
formed on spiral CT scanners with
automated synchronization between
scan commencement and injection of
intravenous iodinated contrast. The
use of newer, faster, multi-slice spiral
scanners may reduce contrast load
[83]. Spiral (spiral = helical) CT scan-
ners include single-slice and multi-
slice scanners but not axial scanners.
• A chest CT with contrast is not equiva-
lent to CT pulmonary angiography.
• Older axial CT scanners cannot perform
CT pulmonary angiography even
though they can produce adequate
chest CT.
• Contrast must be delivered with a
mechanical injector via a peripheral
or central intravenous line at a mini-
mum of 2 ml/sec for a total volume of
120 to 140 ml. It is acceptable to use
an empiric delay between the initia-
tion of contrast injection and scanning
of 20 sec. A contrast timing test-run
(that may be automated on some scan-
ners) before the actual CT angiogram
is necessary in patients with cardiac
dysfunction, since with lower cardiac
output, contrast will take longer to
opacify the arteries [89, 90].
• Evaluation of the peripheral arteries and
minimization of motion is obtained
when slice thickness is lower.Athick-
ness of 3 mm is ideal (5 mm maxi-
mum), and reconstruction to 1 or 1.5
mm thickness is helpful [73].
• The scan should encompass the top of the
diaphragm to the top of the aortic arch
coveringafieldofviewfrominnerribto
inner rib in a caudal to cranial direction
whilethepatientsuspendsrespiration(if
possible). Furthermore, scanning caudal
tocranialimprovescontrastbetweenthe
lower-lobe arteries and veins where
most emboli are found [5, 83, 91-93].
• Incomplete opacification of vessels due
to poor contrast flow rate, insufficient
flow or poor timing, confusing veins
for arteries, mucoid impaction in a
bronchus and hilar lymph nodes may
mimic emboli [94].
Safriel and Hull: Diagnosing pulmonary emboli 161• In ventilated patients, ventilation should
be suspended at high lung volumes to
increase pulmonary resistance and
therefore increase vascular opacifica-
tion [95].
• The radiation dose from CT angiography
is lower than invasive angiography
and can be lowered further with thin
collimation and high pitch [65].
TECHNICAL DETAILS:
CATHETER ANGIOGRAPHY
• For invasive/catheter pulmonary angiog-
raphy, the unit must be capable of pro-
ducing subtracted images.
• All patients undergoing pulmonary
angiography via a femoral vein
approach should have pre-procedure
lower extremity ultrasound to exclude
thrombosis.
• Additional cardiac monitoring is required
during the procedure due to some
patients developing transient RBBB or
cardiac arrhythmia. The primary oper-
ator cannot monitor the patient during
the procedure.Another medical profes-
sional should be available to monitor
ECG strip.
• DSA improves the image quality, and
careful monitoring reduces life threat-
ening complication by early identifi-
cation of rhythm abnormalities
induced by catheter manipulation
within the heart [52, 76, 77].
• If the femoral veins are thrombosed,
attempted vascular access for catheter
angiography may be difficult or cause
embolization of the thrombus.
CATHETER ANGIOGRAPHY-
DIRECTED TREATMENT
Thrombolysis for sub-massive pul-
monary embolism remains controversial.
A recent multi-center trial compared
heparin and alteplase with heparin and
placebo in 256 patients [96]. Hospital stay,
catecholamine use, and secondary throm-
bolysis were higher in the heparin and
placebo group, and mortality was not sta-
tistically significant. Unfortunately, this
study is limited by poor design of use of
heparin (5,000 U bolus) and then 1,000
U/hr in both arms. Standard heparin dos-
ing is a 80 U/kg bolus and 18 U/kg/hr. It is
clear the patients in the heparin arm were
being under-dosed (males average weight
= 86.7 kg [+/- 16.0] and females average
weight = 75.6 kg [+/- 13.6]). Outcome
may have been improved in these patients
had they received adequate initial antico-
agulation. Furthermore the use of lower
levels of heparin may explain why there
was less intracranial hemorrhage than in
prior trials, further biasing the trial.
PATIENT CONSENT ISSUES
Angiography often requires the
patient to sign informed consent. There are
slight but real risks associated with the
procedure.
• In a large-scale series of 547 patients
evaluating the safety of pulmonary
angiography, two patients had
reversible arrhythmias as a result of
the catheter passage through the right
side of the heart, as well as side-
effects to sedatives in two patients.
The overall adverse reaction rate was
4.8 percent without any procedure-
attributable deaths [54]. In a series
evaluating out patient diagnostic
angiography (that did not include pul-
monary angiography), up to 8.6 per-
cent of patients undergoing diagnostic
angiography experience self-limiting
local pain at the catheter insertion site
[97]. The greatest risk to a contrast
reaction is a previous contrast reac-
tion [29]. The risk of all adverse drug
reactions with non-ionic contrast
administration in the general popula-
tion is between 1.2 percent and 3.13
percent [28, 38]. Risks relate to con-
trast administration for all types of
angiography.
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tional risks of invasive catheterization
including infection, vessel damage,
bleeding, and arrhythmias.
• Angiography is usually performed with
the patient not sedated. In the case of
catheter angiography, local anesthesia
is used at the venous access site.
Conscious sedation may be used in
agitated patients but carries its own
risks in patients with already compro-
mised lung functions. For catheter
angiography, the patient has to lie still
on an uncomfortable table for a proce-
dure that may take 60 minutes.
• CT pulmonary angiography takes
between 30 to 90 seconds and requires
the patient to lift their arms above their
hands while holding their breath.
• Allergic contrast reactions usually mani-
fest during the procedure.
• Extravasation of contrast is usually felt
as immediate pain and swelling at the
contrast injection site. Extravasation
of contrast media into soft tissues sur-
rounding a vein during an injection
can lead to tissue damage from direct
toxicity of the contrast agent or from
pressure effects, such as a compart-
ment syndrome. No specific treatment
has been shown unequivocally to be
effective, so most extravasation
injuries are treated conservatively
with supportive measures [46].
• Transient side effects such as flushing,
cramping, and bad taste may occur in
as many as 3.8 percent of patients
receiving non-ionic contrast [98]. In
other series, as many as 10 percent
experience systemic reactions
(including abdominal cramps, slight
fever, nausea) but these are invariably
self limiting [46, 53].
POST PROCEDURE AND
FOLLOW-UP
• In the general population (without risk
factors to contrast administration),
contrast reactions requiring medical
therapy are rare [28, 38]. Adverse
drug reactions will almost always
manifest within 24 hours, the majori-
ty of which manifest while the patient
is still in the radiology suite [23, 28,
32, 33, 41, 42, 46]. Minor drug reac-
tions need not be followed up unless
complications arise.
• Patients with type II diabetes on
Metformin should not resume
Metformin after contrast administra-
tion until a 48-hour renal function has
been checked [43, 46].
• Patients should drink copious amounts of
fluid unless a contraindication to
excessive hydration exists. Hydration
(unless contra-indicated) is the best
proven intervention that reduces renal
toxicity [53].
• Patients with pre-existing diabetes or
renal dysfunction will need to return
to the referring physician for evalua-
tion of renal function. Abnormal rises
in serum creatinine should be evaluat-
ed, and the patient should be treated
or followed until creatinine returns to
pre procedure baseline [23, 33].
• Patients undergoing angiography may
experience injection site pain and
bruising, as well as minor systemic
symptoms. These are self limiting.
• Patients undergoing invasive angiogra-
phy should be at bed rest for six hours
and have reduced activity for 24
hours. In a series evaluating out-
patient diagnostic angiography (that
did not include pulmonary angiogra-
phy), up to 25 percent of patients
undergoing diagnostic angiography
experience self limiting pain and/or
bruising. Yet only 1.5 percent experi-
enced a medically significant adverse
effect (such as renal deterioration,
contrast allergy, etc.) [97]. The higher
rate of pain and bruising can be attrib-
uted to the increased mobility of out-
patients post procedure and empha-
sizes the need for patients to have
Safriel and Hull: Diagnosing pulmonary emboli 163reduced activity for at least 6 hours
post invasive angiography.
• Breast feeding mothers should avoid
breast feeding for 24 hours as iodinat-
ed contrast is excreted in breast milk
and may cause transient neonatal
hypothyroidism.
CONCLUSION
This paper provides a framework to
guide clinicians through the process of
evaluating for the presence of pulmonary
emboli and provides a decision tree for
potential situations (Figure 1). CT pul-
monary angiography has been shown to be
a safe and effective modality for the evalu-
ation of the pulmonary vasculature.
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